TC BioPharm Collaborates with CareDx for Groundbreaking Clinical Trial in Allogeneic Cell Therapy

TC BioPharm Collaborates with CareDx for the ACHIEVE Clinical Trial

TC BioPharm (Holdings) PLC, a cutting-edge clinical-stage biotechnology firm specializing in allogeneic gamma-delta T cell therapies, has recently formed a strategic partnership with CareDx, Inc. This collaboration marks an important milestone in their ongoing efforts to develop innovative healthcare solutions for serious diseases, particularly acute myeloid leukemia (AML).

The joint venture focuses on the ACHIEVE clinical trial, an adaptive and open-label Phase II study aimed at assessing the efficacy and effectiveness of TCB008, a novel allogeneic gamma-delta T cell therapy. The trial will involve patients diagnosed with AML or myelodysplastic syndrome (MDS), conditions that present significant treatment challenges and require alternative therapeutic approaches.

CareDx, renowned for its precision medicine initiatives, will utilize its proprietary AlloCell solution to conduct pharmacokinetic analyses within the ACHIEVE trial. AlloCell is designed specifically for monitoring the expansion and persistence of allogeneic immune and stem cell therapies, making it an invaluable asset for understanding the dynamics of TCB008 within the patients' immune systems.

One of the primary objectives of the ACHIEVE trial is to gather vital data on the behavior of TCB008 in terms of both its expansion and how long it remains active in the patients’ systems. This data is crucial for guiding clinicians in optimizing treatment plans and understanding the immune reconstitution process for AML patients receiving this innovative therapy.

Alison Bracchi, the Executive Vice President of Clinical Operations at TC BioPharm, emphasized the significance of this partnership, stating, "Our collaboration with CareDx is a monumental step towards the successful development and enhancement of TCB008 as a therapeutic option for acute myeloid leukemia and various blood cancers."

Marica Grskovic, PhD, Chief Strategy Officer at CareDx, expressed her excitement about the ongoing advancements in the field of allogeneic cell therapy. She commented, "We are eager to contribute to the scientific progress aimed at transforming the treatment landscape for patients grappling with acute myeloid leukemia. This partnership aligns perfectly with our strategy to broaden our reach into hematology oncology through innovative pharmacokinetic monitoring capabilities."

About TC BioPharm

TC BioPharm is a leader in the realm of clinical-stage biopharmaceuticals, specifically targeting the discovery, development, and marketing of gamma-delta T cell therapies. Their research portfolio boasts human efficacy data related to acute myeloid leukemia treatments, showcasing the potential of gamma-delta T cells—unique immune cells that adeptly differentiate between healthy and diseased tissues.

The company is at the forefront of gamma-delta T cell therapy development and has conducted pivotal Phase II clinical trials in the oncology space. Presently, TC BioPharm is also managing two investigator-initiated clinical trials for its unmodified gamma-delta T cell products, including a Phase 2b/3 pivotal trial using its proprietary allogeneic CryoTC technology to distribute frozen therapy products to clinics globally.

Forward-looking statements reveal that while TC BioPharm aims to maintain momentum in this groundbreaking arena, various risks and uncertainties remain, providing a sobering reminder of the complexities in biomedical research. For more details on their current status and future aspirations, stakeholders are encouraged to review TC BioPharm's reports and updates available on their Investor Relations website.

As this partnership progresses, both TC BioPharm and CareDx are poised to make substantial contributions to the field of cancer therapy, expanding horizons for treatment options for AML patients and paving the way for future innovations in allogeneic cell therapies.